A US Claims-Based Analysis of Real-World Lipid-Lowering Treatment Patterns in Patients With High Cardiovascular Disease Risk or a Previous Coronary Event.

[1]  U. Laufs,et al.  Treatment patterns and low-density lipoprotein cholesterol (LDL-C) goal attainment among patients receiving high- or moderate-intensity statins , 2017, Clinical Research in Cardiology.

[2]  James R. Rogers,et al.  Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi‐Database Cohort Study , 2017, Arthritis & rheumatology.

[3]  J. Garber,et al.  AACE/ACE comprehensive diabetes management algorithm 2015. , 2015, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[4]  H. Bays,et al.  National Lipid Association Annual Summary of Clinical Lipidology 2015. , 2014, Journal of clinical lipidology.

[5]  K. Ethier,et al.  CDC National Health Report: leading causes of morbidity and mortality and associated behavioral risk and protective factors--United States, 2005-2013. , 2014, MMWR supplements.

[6]  D. Kern,et al.  Statin treatment patterns and clinical profile of patients with risk factors for coronary heart disease defined by National Cholesterol Education Program Adult Treatment Panel III , 2014, Current medical research and opinion.

[7]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[8]  S. Grundy,et al.  An assessment by the Statin Intolerance Panel: 2014 update. , 2014, Journal of clinical lipidology.

[9]  J. Stephenson,et al.  Treatment pattern changes in high-risk patients newly initiated on statin monotherapy in a managed care setting. , 2013, Journal of clinical lipidology.

[10]  P. de Groen.  Discontinuation of Statins in Routine Care Settings , 2013, Annals of Internal Medicine.

[11]  A. Turchin,et al.  Discontinuation of Statins in Routine Care Settings , 2013, Annals of Internal Medicine.

[12]  J. McGill,et al.  AACE comprehensive diabetes management algorithm 2013. , 2013, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[13]  Alexander Turchin,et al.  Accuracy of Electronically Reported “Meaningful Use” Clinical Quality Measures , 2013, Annals of Internal Medicine.

[14]  P. Thompson,et al.  Effect of Statins on Skeletal Muscle Function , 2012, Circulation.

[15]  Matthew K Ito,et al.  Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. , 2012, Journal of clinical lipidology.

[16]  Suzanne G. Leveille,et al.  Statin use and musculoskeletal pain among adults with and without arthritis. , 2012, The American journal of medicine.

[17]  R. Hegele,et al.  Diagnosis, prevention, and management of statin adverse effects and intolerance: proceedings of a Canadian Working Group Consensus Conference. , 2011, The Canadian journal of cardiology.

[18]  M. Taskinen,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, Atherosclerosis.

[19]  G. Chodick,et al.  Long-term persistence with statin treatment in a not-for-profit health maintenance organization: a population-based retrospective cohort study in Israel. , 2008, Clinical therapeutics.

[20]  J. Mckenney,et al.  Understanding practice patterns and low-density lipoprotein cholesterol goal attainment implications of switching patients from simvastatin in a health plan setting. , 2007, The American journal of managed care.

[21]  H. Heien,et al.  Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice. , 2007, The American journal of geriatric pharmacotherapy.

[22]  E. Bruckert,et al.  Mild to Moderate Muscular Symptoms with High-Dosage Statin Therapy in Hyperlipidemic Patients —The PRIMO Study , 2005, Cardiovascular Drugs and Therapy.

[23]  A. Walker,et al.  Compliance with a statin treatment in a usual-care setting: retrospective database analysis over 3 years after treatment initiation in health maintenance organization enrollees with dyslipidemia. , 2005, Clinical therapeutics.

[24]  European Atherosclerosis Society Consensus Panel: statins , 2018, Reactions Weekly.

[25]  Z. Ahmad.  Statin intolerance. , 2014, The American journal of cardiology.

[26]  S. Benemei,et al.  Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis. , 2012, Clinical therapeutics.

[27]  A. Catapano.  Perspectives on low-density lipoprotein cholesterol goal achievement. , 2009, Current medical research and opinion.

[28]  J. Benner,et al.  Generic and therapeutic statin switches and disruptions in therapy. , 2009, Current medical research and opinion.

[29]  Matthew A Silva,et al.  Statin-related adverse events: a meta-analysis. , 2006, Clinical therapeutics.

[30]  S. Grundy,et al.  Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines. , 2004, Journal of the American College of Cardiology.